<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Genes (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Genes (Basel)</journal-id><journal-id journal-id-type="publisher-id">genes</journal-id><journal-title-group><journal-title>Genes</journal-title></journal-title-group><issn pub-type="epub">2073-4425</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9408728</article-id><article-id pub-id-type="doi">10.3390/genes13081482</article-id><article-id pub-id-type="publisher-id">genes-13-01482</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Metabolomic Profiling Reveals Common Metabolic Alterations in Plasma of Patients with <italic toggle="yes">Toxoplasma</italic> Infection and Schizophrenia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Osman</surname><given-names>Emelia</given-names></name><xref rid="af1-genes-13-01482" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohammad Zahariluddin</surname><given-names>Anis Safirah</given-names></name><xref rid="af1-genes-13-01482" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2130-739X</contrib-id><name><surname>Sharip</surname><given-names>Shalisah</given-names></name><xref rid="af2-genes-13-01482" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4986-5393</contrib-id><name><surname>Md Idris</surname><given-names>Zulkarnain</given-names></name><xref rid="af1-genes-13-01482" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0824-0581</contrib-id><name><surname>Tan</surname><given-names>Jen Kit</given-names></name><xref rid="af3-genes-13-01482" ref-type="aff">3</xref><xref rid="c1-genes-13-01482" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ferraro</surname><given-names>Thomas N.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Crist</surname><given-names>Richard C.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Buono</surname><given-names>Russell J.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Reiner</surname><given-names>Benjamin C.</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Berrettini</surname><given-names>Wade H.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-genes-13-01482"><label>1</label>Department of Parasitology and Medical Entomology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia</aff><aff id="af2-genes-13-01482"><label>2</label>Department of Psychiatry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia</aff><aff id="af3-genes-13-01482"><label>3</label>Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia</aff><author-notes><corresp id="c1-genes-13-01482"><label>*</label>Correspondence: <email>jenkittan@ukm.edu.my</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>8</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2022</year></pub-date><volume>13</volume><issue>8</issue><elocation-id>1482</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2022</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic toggle="yes">Toxoplasma gondii</italic> is an opportunistic protozoan parasite known to affect the human brain. The infection has been associated with an increased incidence of schizophrenia; however, the link between the two conditions remains unclear. This study aimed to compare the plasma metabolome of schizophrenia and non-schizophrenia subjects with or without <italic toggle="yes">Toxoplasma</italic> infection. Untargeted metabolomic profiling was carried out by liquid chromatography-mass spectrometry. Elevation of the &#x003b1;-hydroxyglutaric acid level and reduced adenosine monophosphate, inosine, hypoxanthine and xanthine were found in the subjects with either toxoplasmosis or schizophrenia alone. These results suggest that purine catabolism is a common metabolic alteration in <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia. The roles of these metabolites on the pathogenesis of schizophrenia in relation to <italic toggle="yes">Toxoplasma</italic> infection warrant further studies.</p></abstract><kwd-group><kwd><italic toggle="yes">Toxoplasma gondii</italic></kwd><kwd>toxoplasmosis</kwd><kwd>schizophrenia</kwd><kwd>metabolomics</kwd><kwd>purine catabolism</kwd></kwd-group><funding-group><award-group><funding-source>Research Incentive Grant</funding-source><award-id>GGP-2017-033</award-id></award-group><funding-statement>This study was funded by the Research Incentive Grant (GGP-2017-033) from the Universiti Kebangsaan Malaysia. </funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-genes-13-01482"><title>1. Introduction</title><p>Infection of <italic toggle="yes">Toxoplasma gondii</italic> affects approximately 33% of the world population [<xref rid="B1-genes-13-01482" ref-type="bibr">1</xref>]. The routes of infection include contact with cat faeces, the ingestion of contaminated meat containing <italic toggle="yes">T. gondii</italic> cysts and vertical transmission from mother to foetus [<xref rid="B2-genes-13-01482" ref-type="bibr">2</xref>]. Infection in pregnant women is a major concern because it can cause spontaneous abortion and stillbirth. Immunocompromised individuals may develop severe toxoplasmosis, leading to encephalitis [<xref rid="B3-genes-13-01482" ref-type="bibr">3</xref>]. Nevertheless, <italic toggle="yes">Toxoplasma</italic> infection is usually asymptomatic in healthy people; however, it persists as a latent infection for life. The parasite prefers to infest brain tissue and might affect brain functions responsible for emotion and thought processes [<xref rid="B1-genes-13-01482" ref-type="bibr">1</xref>]. Numerous studies have shown a positive association between <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia. A higher rate of <italic toggle="yes">Toxoplasma</italic> infection was found in schizophrenia patients than in healthy individuals [<xref rid="B4-genes-13-01482" ref-type="bibr">4</xref>,<xref rid="B5-genes-13-01482" ref-type="bibr">5</xref>,<xref rid="B6-genes-13-01482" ref-type="bibr">6</xref>,<xref rid="B7-genes-13-01482" ref-type="bibr">7</xref>,<xref rid="B8-genes-13-01482" ref-type="bibr">8</xref>]. <italic toggle="yes">Toxoplasma</italic> infection has been shown to change animals&#x02019; behaviours and brain functions; while acute infection has been associated with psychotic symptoms in humans [<xref rid="B9-genes-13-01482" ref-type="bibr">9</xref>]. In addition, <italic toggle="yes">Toxoplasma</italic> infection could alter neurotransmitter metabolisms in the human brain [<xref rid="B10-genes-13-01482" ref-type="bibr">10</xref>].</p><p>Schizophrenia is a psychiatric disorder with an uncertain cause that affects nearly 1% of the world population [<xref rid="B11-genes-13-01482" ref-type="bibr">11</xref>]. Genetic factors appear as a major risk for the disorder; moreover, environmental factors such as infection have been proposed to interact with the predisposing genes, leading to the development of schizophrenia [<xref rid="B1-genes-13-01482" ref-type="bibr">1</xref>]. Given the possible link between <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia, controlling the risk factors such as <italic toggle="yes">Toxoplasma</italic> infection might prevent the development of schizophrenia in later life. However, establishing the link between <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia remains a difficult task because both conditions persist over a long period of time and progress slowly.</p><p>Metabolites are the downstream products and mediators of biochemical pathways in the body. They are often regarded as the closest readout of physiological status. Identification of the metabolic changes in <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia might provide novel insights into the underlying mechanisms of schizophrenia concerning toxoplasmosis. Therefore, this study aimed to compare the plasma metabolome of schizophrenia and non-schizophrenia subjects with or without <italic toggle="yes">Toxoplasma</italic> infection.</p></sec><sec id="sec2-genes-13-01482"><title>2. Materials and Methods</title><sec id="sec2dot1-genes-13-01482"><title>2.1. Participant Recruitment and Sample Collection</title><p>Patients diagnosed with schizophrenia were recruited using convenient sampling when admitted to the psychiatry ward or came for a follow-up at the psychiatric clinic in Hospital Canselor Tuanku Muhriz, Kuala Lumpur from June 2018 to December 2018. The patients were diagnosed clinically by experienced psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V). Immunocompromised patients were excluded from this study. Non-schizophrenia volunteers were recruited from the community. A screening using Mini-International Neuropsychiatric Interview (M.I.N.I) version 7.0.2 for DSM-V was carried out to assess the mental status of the volunteers. All the participants were screened for <italic toggle="yes">Toxoplasma</italic> infection using serological tests and divided into four groups of 15 subjects each: (1) <italic toggle="yes">Toxoplasma</italic> positive and schizophrenia (TP+Sz); (2) <italic toggle="yes">Toxoplasma</italic> positive and non-schizophrenia (T+NSz); (3) <italic toggle="yes">Toxoplasma</italic> negative and schizophrenia (TN+Sz); and (4) <italic toggle="yes">Toxoplasma</italic> negative and non-schizophrenia (TN+NSz). Informed consent was obtained from all the subjects involved in the study.</p><p>A total of 3 mL of blood was taken by venipuncture into an EDTA tube. Blood samples were then centrifuged at 3000&#x000d7; <italic toggle="yes">g</italic> for 15 min to obtain plasma and stored at &#x02212;20 &#x000b0;C until further use. The study was conducted according to the Declaration of Helsinki and was approved by the Research Ethics Committee of the National University of Malaysia (UKM PPI/111/8/JEP-2018-281). All the participants were provided with written informed consent.</p></sec><sec id="sec2dot2-genes-13-01482"><title>2.2. Serological Assay</title><p>The enzyme-linked immunosorbent assay (ELISA) kits (PLATELIA TOXO IgG; Bio-Rad, Marnes-la-Coquette, France) were used to measure the level of specific IgG antibodies against <italic toggle="yes">T. gondii</italic>. All the plasma samples were tested in duplicates following the protocol provided by the manufacturer. A Multiskan FC Microplate Photometer (Thermo Scientific, Waltham, MA, USA) was used to measure the IgG antibody titres at 420 nm with 650 nm as a reference wavelength. SkanIt software (v5.0) was used to analyse the data. A sample was considered as <italic toggle="yes">Toxoplasma</italic> negative if the titres for anti-<italic toggle="yes">T. gondii</italic> IgG antibodies were lower than 6 IU/mL, while values above 9 IU/mL were considered as positive.</p></sec><sec id="sec2dot3-genes-13-01482"><title>2.3. Metabolomic Analysis</title><p>The chemicals used were of mass spectrometry-grade purchased from Fischer Scientific (Hampton, NH, USA). The extraction of metabolites from plasma was performed as described previously, with a slight modification [<xref rid="B12-genes-13-01482" ref-type="bibr">12</xref>]. Briefly, cold methanol was added to 200 &#x000b5;L of plasma at 3:1 ratio, vortexed for 15 s, and centrifuged at 15,800&#x000d7; <italic toggle="yes">g</italic> for 15 min at 4 &#x000b0;C. The supernatant was dried with a vacuum centrifuge (Eppendorf, Hamburg, Germany) at room temperature. The quality control (QC) sample was prepared by pooling an aliquot from each plasma sample, followed by the metabolite extraction procedure identical to the plasma samples. The dried supernatant was reconstituted with water and filtered with a 0.2 &#x000b5;m cellulose regenerated membrane (Fischer Scientific). Water was used as a blank sample. Liquid chromatography-tandem mass spectrometry (LCMS/MS) was performed using a UHPLC system (Dionex Ultimate 3000; Thermo Scientific) and Orbitrap MS (Q Exactive HF; Thermo Scientific). A C18 column (Synchronis; 1.7 &#x000b5;m; 2.1 &#x000d7; 100 mm; Thermo Scientific) was heated at 55 &#x000b0;C with a flow rate of 0.45 mL/min. Water and acetonitrile with 0.1% formic acid each were used as solvent A and B, respectively. The elution gradient for solvent B was 0.5% for 1 min, 0.5 to 99.5% for 15 min, 99.5% for 4 min and 99.5 to 0.5% for 2 min. MS1 was acquired at a resolution of 60,000, while MS2 at 15,000. Fragmentation was performed with a stepped normalized collision energy (NCE) of 20, 40 and 60. The injection volume was set as 2 &#x000b5;L. Negative ionisation mode was acquired after the completion of positive ion mode. The QC sample was injected 5 times in the beginning and once at an interval of every 4 plasma samples. The plasma samples were arranged randomly in between the QC injections.</p><p>Raw data files were pre-processed with the Compound Discoverer 2.0 (Thermo Scientific) for peak detection and alignment and background subtraction. Molecular features (MFs) with molecular weight, retention time and signal intensity were exported as a csv file. Statistical analysis was carried out by MetaboAnalyst 4.0 [<xref rid="B13-genes-13-01482" ref-type="bibr">13</xref>]. Briefly, the MFs were grouped based on mass and a retention time tolerance of 0.025 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> and 30 s, respectively. The peaks were normalised by cube root and log transformation for positive and negative mode, respectively. All the data were auto-scaled. Differentially expressed molecular features (DeMFs) were identified by a <italic toggle="yes">t</italic>-test with a false discovery rate (FDR) &#x0003c; 0.05. Batch effect was corrected by the Combat method [<xref rid="B14-genes-13-01482" ref-type="bibr">14</xref>] using MetaboAnalyst.</p><p>DeMFs were annotated by cross-checking with the mzCloud database (HighChem LLC, Bratislava, Slovakia), Human Metabolome Database (HMDB) [<xref rid="B15-genes-13-01482" ref-type="bibr">15</xref>] and METLIN [<xref rid="B16-genes-13-01482" ref-type="bibr">16</xref>]. Metabolites that matched with the databases at an accurate mass &#x02264; 5 ppm and MS2 spectrum &#x02265; 70% similarity were assigned as level 2 confidence annotation [<xref rid="B17-genes-13-01482" ref-type="bibr">17</xref>] and reported in this study.</p></sec></sec><sec sec-type="results" id="sec3-genes-13-01482"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-genes-13-01482"><title>3.1. Demographic and Clinical Data of the Participants</title><p>The mean age of the four groups ranged from 32 to 44 years old, with the youngest being 19 and the oldest at 65 years old (<xref rid="genes-13-01482-t001" ref-type="table">Table 1</xref>). The age group of TP+Sz (44.1 years) was significantly higher than TN+Sz (36.3) and TN+NSz (32.4). All the groups consisted of almost equal gender proportion, with the male participants ranging from 40 to 53.3%. Schizophrenia patients were presented with various clinical features. All of them were on medications for their disorder, with some of them having drugs with anti-toxoplasmic activities (40% of TP+Sz and 86.7% of TN+Sz). Almost half of the participants (46.7 to 66.7%) in each group had cat(s) as a pet.</p></sec><sec id="sec3dot2-genes-13-01482"><title>3.2. Integrity of Metabolomic Data</title><p>One sample of TP+NSz in positive mode was identified as an outlier and removed from the analysis (<xref rid="app1-genes-13-01482" ref-type="app">Supplementary Figure S1A</xref>). After removing the outlier, the QC samples in the positive mode were grouped into two clusters in the PCA score plot; this indicated the existence of batch effect (<xref rid="app1-genes-13-01482" ref-type="app">Supplementary Figure S1C</xref>). After batch effect adjustment, the QC samples were clustered together in the score plot (<xref rid="app1-genes-13-01482" ref-type="app">Supplementary Figure S1D</xref>). The QC samples of the negative mode were clustered together with the score plot, except the first QC sample; this indicated an insufficient equilibrium on the first injection (<xref rid="app1-genes-13-01482" ref-type="app">Supplementary Figure S1B</xref>). No plasma samples appeared as an outlier in the negative ion mode.</p><p>By comparing the plasma samples without QC, there was no distinct separation between the compared groups in both the positive (<xref rid="genes-13-01482-f001" ref-type="fig">Figure 1</xref>) and negative (<xref rid="genes-13-01482-f002" ref-type="fig">Figure 2</xref>) modes. These results indicate the difference in metabolic profiles between the groups was subtle. A total of 1031 and 611 MFs were detected in the positive and negative modes, respectively (<xref rid="genes-13-01482-t002" ref-type="table">Table 2</xref>). Fifty-seven DeMFs were found between TP+NSz and TN+NSz; however, only six of these were identified confidently. No DeMF was found between TP+Sz and TN+Sz; while 7 out of 76 DeMFs were identified between TN+Sz and TN+NSz. One out of the five DeMFs was identified between TP+Sz and TP+NSz.</p></sec><sec id="sec3dot3-genes-13-01482"><title>3.3. Metabolite Changes in Toxoplasma Infection and Schizophrenia</title><p>Compared with TN+NSz, the hydroxyglutaric acid level was higher; while adenosine monophosphate, inosine and hypoxanthine were lower in TP+NSz and TN+Sz (<xref rid="genes-13-01482-t003" ref-type="table">Table 3</xref>; <xref rid="app1-genes-13-01482" ref-type="app">Supplementary Figure S2</xref>). These findings suggest that the metabolic pathways related to these metabolites were altered by <italic toggle="yes">Toxoplasma</italic> infection or schizophrenia alone. Compared with TN+NSz, xanthine was lower in TN+Sz, implying that xanthine was reduced in schizophrenia.</p></sec></sec><sec sec-type="discussion" id="sec4-genes-13-01482"><title>4. Discussion</title><p>Exposure to <italic toggle="yes">Toxoplasma</italic> could be a risk factor for schizophrenia. The mechanism and multifaceted effects by which toxoplasmosis could be involved in the onset of the disease are just starting to be understood. Recently, a study by El Mouhawass et al., (2020) revealed the presence of a gene polymorphism encoding matrix metallopeptidase-9 (MMP-9) proteins in patients who presented with both schizophrenia and toxoplasmosis [<xref rid="B18-genes-13-01482" ref-type="bibr">18</xref>]. The study postulated that the expression of this polymorphism could promote the invasion of immune cells infected by <italic toggle="yes">T. gondii</italic> and stimulate nerve cells to produce the neurotransmitters involved; this would result in the occurrence of schizophrenia. In addition, a metabolomic analysis could be another approach to ascertain the underlying mechanism of schizophrenia following <italic toggle="yes">T. gond</italic><italic toggle="yes">ii</italic> infection. In the current study, we detected common metabolites present in plasma samples of schizophrenia and non-schizophrenia subjects with or without <italic toggle="yes">Toxoplasma</italic> infection that may fill the gap in understanding the pathogenesis of schizophrenia related to <italic toggle="yes">T. gondii</italic> infection.</p><p>The biosynthesis of purine nucleotides in humans can be divided into <italic toggle="yes">de novo</italic> and salvage pathways [<xref rid="B19-genes-13-01482" ref-type="bibr">19</xref>]. <italic toggle="yes">T. gondii</italic> is a purine auxotroph that relies entirely on the latter pathway for the biosynthesis of purine nucleotides [<xref rid="B20-genes-13-01482" ref-type="bibr">20</xref>]. The parasite captures free forms of purine bases from the host and transports them into its cytosol for the energy-saving salvage pathway. Although the enzymes in this pathway of the parasite and the transport of purine bases from the host to the parasite are well-studied [<xref rid="B21-genes-13-01482" ref-type="bibr">21</xref>,<xref rid="B22-genes-13-01482" ref-type="bibr">22</xref>,<xref rid="B23-genes-13-01482" ref-type="bibr">23</xref>], the alteration of purine metabolism in humans with <italic toggle="yes">Toxoplasma</italic> infection has not been reported. Intermediates of the host&#x02019;s purine catabolism, such as adenosine, hypoxanthine, inosine and xanthine, can be used by <italic toggle="yes">T. gondii</italic> to synthesise its purine nucleotides [<xref rid="B24-genes-13-01482" ref-type="bibr">24</xref>]. Our results show that adenosine monophosphate, inosine and hypoxanthine levels were decreased in the plasma of non-schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection compared to subjects without both conditions; implying that intermediates of purine catabolism are reduced with <italic toggle="yes">Toxoplasma</italic> infection. The reduction of these metabolites could be attributed to the consumption of the host&#x02019;s purine catabolism intermediates by the parasite for its nutrient retrieval and energy requirement fulfilment.</p><p>The present study also managed to highlight a decrease in the intermediates of the purine catabolism (inosine, hypoxanthine and xanthine) in <italic toggle="yes">Toxoplasma</italic>-negative schizophrenia patients when compared to subjects that did not have both conditions. Xanthine and hypoxanthine levels are unaffected in first-episode neuroleptic-na&#x000ef;ve patients with schizophrenia [<xref rid="B25-genes-13-01482" ref-type="bibr">25</xref>]; while the increased level of xanthine was reported in medication-free patients with schizophrenia spectrum disorder [<xref rid="B19-genes-13-01482" ref-type="bibr">19</xref>]. The contradictory findings could be attributed to the course of the disease on the levels of these metabolites. The schizophrenia patients in this study were on various antipsychotic medications, with their effects on purine catabolism largely unknown. However, it is unlikely that the use of antipsychotic drugs might account for the altered purine catabolism in these patients as varying types of drugs were prescribed; this makes it less plausible that all these medications had the same effect. Therefore, we postulate that the reduction of these intermediates in purine catabolism was associated with schizophrenia. Taken together, the down-regulation of purine catabolism appears to be a common metabolic alteration in <italic toggle="yes">Toxoplasma</italic> infection or schizophrenia alone. However, the possibility of the pathway linking <italic toggle="yes">Toxoplasma</italic> infection to the underlying pathogenesis of schizophrenia requires further investigation. The alterations of purine catabolism in <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia patients are shown in <xref rid="genes-13-01482-f003" ref-type="fig">Figure 3</xref>.</p><p>An increased level of &#x003b1;-hydroxyglutaric acid is found in 22q11.2 deletion syndrome [<xref rid="B26-genes-13-01482" ref-type="bibr">26</xref>]. This syndrome is one of the risk factors for schizophrenia; it is characterised by neurobehavioral and cognitive development changes. Moreover, elevated levels of the compound are also present in patients with bipolar disorder [<xref rid="B27-genes-13-01482" ref-type="bibr">27</xref>]. Interestingly, our data showed that the &#x003b1;-hydroxyglutaric acid level was increased in schizophrenia patients without <italic toggle="yes">Toxoplasma</italic> infection compared with subjects without both conditions. These observations indicate that the accumulation of &#x003b1;-hydroxyglutaric acid might be associated with psychotic disorders due to its effect on brain functions. The potential of &#x003b1;-hydroxyglutaric acid as a biomarker for schizophrenia and its mechanistic action requires further investigation.</p><p>The association between &#x003b1;-hydroxyglutaric acid levels and <italic toggle="yes">Toxoplasma</italic> infection has not been reported to date. Our results show that the &#x003b1;-hydroxyglutaric acid level was elevated in non-schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection compared to subjects without both conditions. Due to the possible link of &#x003b1;-hydroxyglutaric acid to schizophrenia, the relationship between <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia might be explained by the elevated level of &#x003b1;-hydroxyglutaric acid. Accumulation of &#x003b1;-hydroxyglutaric acid due to <italic toggle="yes">Toxoplasma</italic> infection might be implicated in the pathogenesis of schizophrenia.</p><p>In this study, adenosine monophosphate, inosine, hypoxanthine, xanthine and &#x003b1;-hydroxyglutaric acid levels remained unchanged in subjects with both conditions compared with subjects with either condition. These findings suggest a lack of synergistic effect of <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia on purine catabolism and &#x003b1;-hydroxyglutaric acid levels. Another possible explanation is that either condition is sufficient to elicit the maximal alteration to the levels of these metabolites.</p><p>This study contains several limitations. Firstly, the influence of antipsychotic medications and lifestyle factors, such as having cat(s) as pet, smoking, consuming alcohol and body mass index, on the metabolic pathways could not be excluded. Secondly, the sample size for each group was small. Thirdly, most of the DeMFs were not identified. Hence, further studies with a larger sample size that consider the first-episode neuroleptic-na&#x000ef;ve patients or medication-free chronic patients and their lifestyle factors are required to verify our findings. In addition, targeted metabolomic approaches could be carried out to complement the results of this study.</p><p>Despite these limitations, the current findings support schizophrenia research in the future to identify the direct connection of toxoplasmosis with schizophrenia and the mechanisms involved. These could provide crucial scientific evidence that shifts the paradigms of diagnosing and treating schizophrenia patients by considering the infection.</p></sec><sec sec-type="conclusions" id="sec5-genes-13-01482"><title>5. Conclusions</title><p>In conclusion, this study reveals that <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia share some common metabolic alterations. These changes include the accumulation of &#x003b1;-hydroxyglutaric acid and a decrease of adenosine monophosphate, inosine, hypoxanthine and xanthine; this indicates a reduction of purine catabolism. These metabolites might serve as the link between <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia, explaining the underlying pathogenesis of schizophrenia concerning <italic toggle="yes">Toxoplasma</italic> infection as a risk factor.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to extend our gratitude to Wathiqah Wahid and Zuri Shahidii Kadir for their support and technical assistance in this study.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-genes-13-01482"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/genes13081482/s1">https://www.mdpi.com/article/10.3390/genes13081482/s1</uri>, Figure S1: Distribution of QC and plasma samples in PCA score plot; Figure S2: Boxplots of (A) adenosine monophosphate, (B) inosine, (C) hypoxanthine, (D) xanthine, (E) uric acid and (F) &#x003b1;-hydroxyglutaric acid.</p><supplementary-material id="genes-13-01482-s001" position="float" content-type="local-data"><media xlink:href="genes-13-01482-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, E.O. and J.K.T.; formal analysis, A.S.M.Z. and J.K.T.; funding acquisition, E.O.; methodology, A.S.M.Z. and J.K.T.; supervision, E.O., S.S. and Z.M.I.; writing&#x02014;original draft, E.O. and J.K.T.; writing&#x02014;review and editing, A.S.M.Z., S.S., Z.M.I. and J.K.T. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Research Ethics Committee of the National University of Malaysia (protocol code UKM PPI/111/8/JEP-2018-281, on 11 June 2018).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all the subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data will be available for others to request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-genes-13-01482"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fuglewicz</surname><given-names>A.J.</given-names></name>
<name><surname>Piotrowski</surname><given-names>P.</given-names></name>
<name><surname>Stodolak</surname><given-names>A.</given-names></name>
</person-group><article-title>Relationship between toxoplasmosis and schizophrenia: A review</article-title><source>Adv. Clin. Exp. Med.</source><year>2017</year><volume>26</volume><fpage>1031</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.17219/acem/61435</pub-id><?supplied-pmid 29068607?><pub-id pub-id-type="pmid">29068607</pub-id></element-citation></ref><ref id="B2-genes-13-01482"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McAuley</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Congenital toxoplasmosis</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2014</year><volume>3</volume><fpage>S30</fpage><lpage>S35</lpage><pub-id pub-id-type="doi">10.1093/jpids/piu077</pub-id><?supplied-pmid 25232475?><pub-id pub-id-type="pmid">25232475</pub-id></element-citation></ref><ref id="B3-genes-13-01482"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nimir</surname><given-names>A.R.</given-names></name>
<name><surname>Osman</surname><given-names>E.</given-names></name>
<name><surname>Ibrahim</surname><given-names>I.A.A.</given-names></name>
<name><surname>Saliem</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Is it toxoplasma encephalitis, HIV encephalopathy or brain tuberculoma?</article-title><source>BMJ Case Rep.</source><year>2013</year><volume>2013</volume><fpage>bcr2013008803</fpage><pub-id pub-id-type="doi">10.1136/bcr-2013-008803</pub-id><?supplied-pmid 23580678?><pub-id pub-id-type="pmid">23580678</pub-id></element-citation></ref><ref id="B4-genes-13-01482"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torrey</surname><given-names>E.F.</given-names></name>
<name><surname>Yolken</surname><given-names>R.H.</given-names></name>
</person-group><article-title><italic toggle="yes">Toxoplasma gondii</italic> and schizophrenia</article-title><source>Emerg. Infect. Dis.</source><year>2003</year><volume>9</volume><fpage>1375</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.3201/eid0911.030143</pub-id><pub-id pub-id-type="pmid">14725265</pub-id></element-citation></ref><ref id="B5-genes-13-01482"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torrey</surname><given-names>E.F.</given-names></name>
<name><surname>Bartko</surname><given-names>J.J.</given-names></name>
<name><surname>Yolken</surname><given-names>R.H.</given-names></name>
</person-group><article-title><italic toggle="yes">Toxoplasma gondii</italic> and other risk factors for schizophrenia: An update</article-title><source>Schizophr. Bull.</source><year>2012</year><volume>38</volume><fpage>642</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbs043</pub-id><pub-id pub-id-type="pmid">22446566</pub-id></element-citation></ref><ref id="B6-genes-13-01482"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Emelia</surname><given-names>O.</given-names></name>
<name><surname>Amal</surname><given-names>R.N.</given-names></name>
<name><surname>Ruzanna</surname><given-names>Z.Z.</given-names></name>
<name><surname>Shahida</surname><given-names>H.</given-names></name>
<name><surname>Azzubair</surname><given-names>Z.</given-names></name>
<name><surname>Tan</surname><given-names>K.S.</given-names></name>
<name><surname>Noor Aadila</surname><given-names>S.</given-names></name>
<name><surname>Siti</surname><given-names>N.A.M.</given-names></name>
<name><surname>Aisah</surname><given-names>M.Y.</given-names></name>
</person-group><article-title>Seroprevalence of anti-<italic toggle="yes">Toxoplasma gondii</italic> IgG antibody in patients with schizophrenia</article-title><source>Trop. Biomed.</source><year>2012</year><volume>29</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">22543615</pub-id></element-citation></ref><ref id="B7-genes-13-01482"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flegr</surname><given-names>J.</given-names></name>
<name><surname>Hor&#x000e1;&#x0010d;ek</surname><given-names>J.</given-names></name>
</person-group><article-title>Negative Effects of Latent Toxoplasmosis on Mental Health</article-title><source>Front. Psychiatry</source><year>2020</year><volume>31</volume><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.3389/fpsyt.2019.01012</pub-id></element-citation></ref><ref id="B8-genes-13-01482"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Omar</surname><given-names>A.</given-names></name>
<name><surname>Bakar</surname><given-names>O.C.</given-names></name>
<name><surname>Adam</surname><given-names>N.F.</given-names></name>
<name><surname>Osman</surname><given-names>H.</given-names></name>
<name><surname>Osman</surname><given-names>A.</given-names></name>
<name><surname>Suleiman</surname><given-names>A.H.</given-names></name>
<name><surname>Manaf</surname><given-names>M.R.A.</given-names></name>
<name><surname>Selamat</surname><given-names>M.I.</given-names></name>
</person-group><article-title>Seropositivity and serointensity of <italic toggle="yes">Toxoplasma gondii</italic> antibodies and DNA among patients with schizophrenia</article-title><source>Korean J. Parasitol.</source><year>2015</year><volume>53</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.3347/kjp.2015.53.1.29</pub-id><pub-id pub-id-type="pmid">25748706</pub-id></element-citation></ref><ref id="B9-genes-13-01482"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yolken</surname><given-names>R.H.</given-names></name>
<name><surname>Dickerson</surname><given-names>F.B.</given-names></name>
<name><surname>Fuller Torrey</surname><given-names>E.</given-names></name>
</person-group><article-title>Toxoplasma and schizophrenia</article-title><source>Parasite Immunol.</source><year>2009</year><volume>31</volume><fpage>706</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.2009.01131.x</pub-id><pub-id pub-id-type="pmid">19825110</pub-id></element-citation></ref><ref id="B10-genes-13-01482"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elsheikha</surname><given-names>H.M.</given-names></name>
<name><surname>B&#x000fc;sselberg</surname><given-names>D.</given-names></name>
<name><surname>Zhu</surname><given-names>X.Q.</given-names></name>
</person-group><article-title>The known and missing links between <italic toggle="yes">Toxoplasma gondii</italic> and schizophrenia</article-title><source>Metab. Brain Dis.</source><year>2016</year><volume>31</volume><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1007/s11011-016-9822-1</pub-id><pub-id pub-id-type="pmid">27041387</pub-id></element-citation></ref><ref id="B11-genes-13-01482"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marder</surname><given-names>S.R.</given-names></name>
<name><surname>Cannon</surname><given-names>T.D.</given-names></name>
</person-group><article-title>Schizophrenia</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>1753</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1808803</pub-id><pub-id pub-id-type="pmid">31665579</pub-id></element-citation></ref><ref id="B12-genes-13-01482"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunn</surname><given-names>W.B.</given-names></name>
<name><surname>Broadhurst</surname><given-names>D.</given-names></name>
<name><surname>Begley</surname><given-names>P.</given-names></name>
<name><surname>Zelena</surname><given-names>E.</given-names></name>
<name><surname>Francis-Mcintyre</surname><given-names>S.</given-names></name>
<name><surname>Anderson</surname><given-names>N.</given-names></name>
<name><surname>Brown</surname><given-names>M.</given-names></name>
<name><surname>Knowles</surname><given-names>J.D.</given-names></name>
<name><surname>Halsall</surname><given-names>A.</given-names></name>
<name><surname>Haselden</surname><given-names>J.N.</given-names></name>
<etal/>
</person-group><article-title>Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry</article-title><source>Nat. Protoc.</source><year>2011</year><volume>6</volume><fpage>1060</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1038/nprot.2011.335</pub-id><pub-id pub-id-type="pmid">21720319</pub-id></element-citation></ref><ref id="B13-genes-13-01482"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chong</surname><given-names>J.</given-names></name>
<name><surname>Soufan</surname><given-names>O.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Caraus</surname><given-names>I.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Bourque</surname><given-names>G.</given-names></name>
<name><surname>Wishart</surname><given-names>D.S.</given-names></name>
<name><surname>Xia</surname><given-names>J.</given-names></name>
</person-group><article-title>MetaboAnalyst 4.0: Towards more transparent and integrative metabolomics analysis</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>W486</fpage><lpage>W494</lpage><pub-id pub-id-type="doi">10.1093/nar/gky310</pub-id><pub-id pub-id-type="pmid">29762782</pub-id></element-citation></ref><ref id="B14-genes-13-01482"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>W.E.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Rabinovic</surname><given-names>A.</given-names></name>
</person-group><article-title>Adjusting batch effects in microarray expression data using empirical Bayes methods</article-title><source>Biostatistics</source><year>2007</year><volume>8</volume><fpage>118</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxj037</pub-id><pub-id pub-id-type="pmid">16632515</pub-id></element-citation></ref><ref id="B15-genes-13-01482"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wishart</surname><given-names>D.S.</given-names></name>
<name><surname>Feunang</surname><given-names>Y.D.</given-names></name>
<name><surname>Marcu</surname><given-names>A.</given-names></name>
<name><surname>Guo</surname><given-names>A.C.</given-names></name>
<name><surname>Liang</surname><given-names>K.</given-names></name>
<name><surname>V&#x000e1;zquez-Fresno</surname><given-names>R.</given-names></name>
<name><surname>Sajed</surname><given-names>T.</given-names></name>
<name><surname>Johnson</surname><given-names>D.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Karu</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>HMDB 4.0: The human metabolome database for 2018</article-title><source>Nucleic Acids Res.</source><year>2018</year><volume>46</volume><fpage>D608</fpage><lpage>D617</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1089</pub-id><pub-id pub-id-type="pmid">29140435</pub-id></element-citation></ref><ref id="B16-genes-13-01482"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guijas</surname><given-names>C.</given-names></name>
<name><surname>Montenegro-Burke</surname><given-names>J.R.</given-names></name>
<name><surname>Domingo-Almenara</surname><given-names>X.</given-names></name>
<name><surname>Palermo</surname><given-names>A.</given-names></name>
<name><surname>Warth</surname><given-names>B.</given-names></name>
<name><surname>Hermann</surname><given-names>G.</given-names></name>
<name><surname>Koellensperger</surname><given-names>G.</given-names></name>
<name><surname>Huan</surname><given-names>T.</given-names></name>
<name><surname>Uritboonthai</surname><given-names>W.</given-names></name>
<name><surname>Aisporna</surname><given-names>A.E.</given-names></name>
<etal/>
</person-group><article-title>METLIN: A technology platform for identifying knowns and unknowns</article-title><source>Anal. Chem.</source><year>2018</year><volume>90</volume><fpage>3156</fpage><lpage>3164</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.7b04424</pub-id><pub-id pub-id-type="pmid">29381867</pub-id></element-citation></ref><ref id="B17-genes-13-01482"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sumner</surname><given-names>L.W.</given-names></name>
<name><surname>Amberg</surname><given-names>A.</given-names></name>
<name><surname>Barrett</surname><given-names>D.</given-names></name>
<name><surname>Beale</surname><given-names>M.H.</given-names></name>
<name><surname>Beger</surname><given-names>R.</given-names></name>
<name><surname>Daykin</surname><given-names>C.A.</given-names></name>
<name><surname>Fan</surname><given-names>T.W.-M.</given-names></name>
<name><surname>Fiehn</surname><given-names>O.</given-names></name>
<name><surname>Goodacre</surname><given-names>R.</given-names></name>
<name><surname>Griffin</surname><given-names>J.L.</given-names></name>
<etal/>
</person-group><article-title>Proposed minimum reporting standards for chemical analysis</article-title><source>Metabolomics</source><year>2007</year><volume>3</volume><fpage>211</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1007/s11306-007-0082-2</pub-id><pub-id pub-id-type="pmid">24039616</pub-id></element-citation></ref><ref id="B18-genes-13-01482"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El Mouhawess</surname><given-names>A.</given-names></name>
<name><surname>Hammoud</surname><given-names>A.</given-names></name>
<name><surname>Zoghbi</surname><given-names>M.</given-names></name>
<name><surname>Hallit</surname><given-names>S.</given-names></name>
<name><surname>Haddad</surname><given-names>C.</given-names></name>
<name><surname>El Haddad</surname><given-names>K.</given-names></name>
<name><surname>El Khoury</surname><given-names>S.</given-names></name>
<name><surname>Tannous</surname><given-names>J.</given-names></name>
<name><surname>Obeid</surname><given-names>S.</given-names></name>
<name><surname>Halabi</surname><given-names>M.A.</given-names></name>
<etal/>
</person-group><article-title>Relationship between <italic toggle="yes">Toxoplasma gondii</italic> seropositivity and schizophrenia in the Lebanese population: Potential implication of genetic polymorphism of MMP-9</article-title><source>BMC Psychiatry</source><year>2020</year><volume>20</volume><elocation-id>264</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-020-02683-0</pub-id><pub-id pub-id-type="pmid">32460746</pub-id></element-citation></ref><ref id="B19-genes-13-01482"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>J.K.</given-names></name>
<name><surname>Dougherty</surname><given-names>G.G.</given-names></name>
<name><surname>Reddy</surname><given-names>R.D.</given-names></name>
<name><surname>Keshavan</surname><given-names>M.S.</given-names></name>
<name><surname>Montrose</surname><given-names>D.M.</given-names></name>
<name><surname>Matson</surname><given-names>W.R.</given-names></name>
<name><surname>McEvoy</surname><given-names>J.</given-names></name>
<name><surname>Kaddurah-Daouk</surname><given-names>R.</given-names></name>
</person-group><article-title>Homeostatic imbalance of purine catabolism in first-episode neuroleptic-na&#x000ef;ve patients with schizophrenia</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e9508</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0009508</pub-id><pub-id pub-id-type="pmid">20209081</pub-id></element-citation></ref><ref id="B20-genes-13-01482"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gh&#x000e9;rardi</surname><given-names>A.</given-names></name>
<name><surname>Sarciron</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Molecules targeting the purine salvage pathway in Apicomplexan parasites</article-title><source>Trends Parasitol.</source><year>2007</year><volume>23</volume><fpage>384</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2007.06.003</pub-id><pub-id pub-id-type="pmid">17574921</pub-id></element-citation></ref><ref id="B21-genes-13-01482"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De-Koning</surname><given-names>H.P.</given-names></name>
<name><surname>Al-Salabi</surname><given-names>M.I.</given-names></name>
<name><surname>Cohen</surname><given-names>A.M.</given-names></name>
<name><surname>Coombs</surname><given-names>G.H.</given-names></name>
<name><surname>Wastling</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Identification and characterisation of high affinity nucleoside and nucleobase transporters in <italic toggle="yes">Toxoplasma gondii</italic></article-title><source>Int. J. Parasitol.</source><year>2003</year><volume>33</volume><fpage>821</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1016/S0020-7519(03)00091-2</pub-id><pub-id pub-id-type="pmid">12865082</pub-id></element-citation></ref><ref id="B22-genes-13-01482"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaudhary</surname><given-names>K.</given-names></name>
<name><surname>Darling</surname><given-names>J.A.</given-names></name>
<name><surname>Fohl</surname><given-names>L.M.</given-names></name>
<name><surname>Sullivan</surname><given-names>W.J.</given-names></name>
<name><surname>Donald</surname><given-names>R.G.K.</given-names></name>
<name><surname>Pfefferkorn</surname><given-names>E.R.</given-names></name>
<name><surname>Ullman</surname><given-names>B.</given-names></name>
<name><surname>Roost</surname><given-names>D.S.</given-names></name>
</person-group><article-title>Purine salvage pathways in the apicomplexan parasite <italic toggle="yes">Toxoplasma gondii</italic></article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>31224</fpage><lpage>31227</lpage><pub-id pub-id-type="doi">10.1074/jbc.M404232200</pub-id></element-citation></ref><ref id="B23-genes-13-01482"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaudhary</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>M.T.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Roos</surname><given-names>D.S.</given-names></name>
</person-group><article-title><italic toggle="yes">Toxoplasma gondii</italic> purine nucleoside phosphorylase biochemical characterization, inhibitor profiles, and comparison with the <italic toggle="yes">Plasmodium falciparum</italic> ortholog</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>25652</fpage><lpage>25658</lpage><pub-id pub-id-type="doi">10.1074/jbc.M602624200</pub-id><pub-id pub-id-type="pmid">16829527</pub-id></element-citation></ref><ref id="B24-genes-13-01482"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krug</surname><given-names>E.C.</given-names></name>
<name><surname>Marr</surname><given-names>J.J.</given-names></name>
<name><surname>Berens</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Purine metabolism in <italic toggle="yes">Toxoplasma gondii</italic></article-title><source>J. Biol. Chem.</source><year>1989</year><volume>264</volume><fpage>10601</fpage><lpage>10607</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)81663-5</pub-id><pub-id pub-id-type="pmid">2732241</pub-id></element-citation></ref><ref id="B25-genes-13-01482"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steen</surname><given-names>N.E.</given-names></name>
<name><surname>Dieset</surname><given-names>I.</given-names></name>
<name><surname>Hope</surname><given-names>S.</given-names></name>
<name><surname>Vedal</surname><given-names>T.S.J.</given-names></name>
<name><surname>Smeland</surname><given-names>O.B.</given-names></name>
<name><surname>Matson</surname><given-names>W.</given-names></name>
<name><surname>Kaddurah-Daouk</surname><given-names>R.</given-names></name>
<name><surname>Agartz</surname><given-names>I.</given-names></name>
<name><surname>Melle</surname><given-names>I.</given-names></name>
<name><surname>Djurovic</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders</article-title><source>Psychol. Med.</source><year>2020</year><volume>50</volume><fpage>595</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1017/S0033291719000400</pub-id><pub-id pub-id-type="pmid">30867076</pub-id></element-citation></ref><ref id="B26-genes-13-01482"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Napoli</surname><given-names>E.</given-names></name>
<name><surname>Tassone</surname><given-names>F.</given-names></name>
<name><surname>Wong</surname><given-names>S.</given-names></name>
<name><surname>Angkustsiri</surname><given-names>K.</given-names></name>
<name><surname>Simon</surname><given-names>T.J.</given-names></name>
<name><surname>Song</surname><given-names>G.</given-names></name>
<name><surname>Giulivi</surname><given-names>C.</given-names></name>
</person-group><article-title>Mitochondrial citrate transporter-dependent metabolic signature in the 22q11.2 deletion syndrome</article-title><source>J. Biol. Chem.</source><year>2015</year><volume>290</volume><fpage>23240</fpage><lpage>23253</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.672360</pub-id><?supplied-pmid 26221035?><pub-id pub-id-type="pmid">26221035</pub-id></element-citation></ref><ref id="B27-genes-13-01482"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoshimi</surname><given-names>N.</given-names></name>
<name><surname>Futamura</surname><given-names>T.</given-names></name>
<name><surname>Kakumoto</surname><given-names>K.</given-names></name>
<name><surname>Salehi</surname><given-names>A.M.</given-names></name>
<name><surname>Sellgren</surname><given-names>C.M.</given-names></name>
<name><surname>Holm&#x000e9;n-Larsson</surname><given-names>J.</given-names></name>
<name><surname>Jakobsson</surname><given-names>J.</given-names></name>
<name><surname>P&#x000e5;lsson</surname><given-names>E.</given-names></name>
<name><surname>Land&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Hashimoto</surname><given-names>K.</given-names></name>
</person-group><article-title>Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder</article-title><source>BBA Clin.</source><year>2016</year><volume>5</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.bbacli.2016.03.008</pub-id><pub-id pub-id-type="pmid">27114925</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="genes-13-01482-f001"><label>Figure 1</label><caption><p>Distribution of the plasma samples from positive mode in PCA score plots for different group comparisons. Comparisons were made for (<bold>A</bold>) TP+NSz vs. TN+NSz, (<bold>B</bold>) TP+Sz vs. TN+Sz, (<bold>C</bold>) TN+Sz vs. TN+NSz and (<bold>D</bold>) TP+Sz vs. TP+NSz. TP+NSz: non-schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+NSz: non-schizophrenia subjects without <italic toggle="yes">Toxoplasma</italic> infection; TP+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection.</p></caption><graphic xlink:href="genes-13-01482-g001" position="float"/></fig><fig position="float" id="genes-13-01482-f002"><label>Figure 2</label><caption><p>Distribution of the plasma samples from negative mode in PCA score plots for different group comparisons. Comparisons were made for (<bold>A</bold>) TP+NSz vs. TN+NSz, (<bold>B</bold>) TP+Sz vs. TN+Sz, (<bold>C</bold>) TN+Sz vs. TN+NSz and (<bold>D</bold>) TP+Sz vs. TP+NSz. TP+NSz: non-schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+NSz: non-schizophrenia subjects without <italic toggle="yes">Toxoplasma</italic> infection; TP+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection.</p></caption><graphic xlink:href="genes-13-01482-g002" position="float"/></fig><fig position="float" id="genes-13-01482-f003"><label>Figure 3</label><caption><p>Alteration of the purine catabolic pathway in <italic toggle="yes">Toxoplasma</italic> infection and schizophrenia. The down arrow indicates a down-regulated level. AMP: adenosine monophosphate; GMP: guanosine monophosphate; IMP: inosine monophosphate.</p></caption><graphic xlink:href="genes-13-01482-g003" position="float"/></fig><table-wrap position="float" id="genes-13-01482-t001"><object-id pub-id-type="pii">genes-13-01482-t001_Table 1</object-id><label>Table 1</label><caption><p>Socio-demographic and clinical data of the participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TP+Sz</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TN+Sz</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TP+NSz</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TN+NSz</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Number (N)</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>General</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age in years, mean &#x000b1; SD</td><td align="center" valign="middle" rowspan="1" colspan="1">44.1 &#x000b1; 11.5</td><td align="center" valign="middle" rowspan="1" colspan="1">34 &#x000b1; 7.8 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">36.3 &#x000b1; 12.5</td><td align="center" valign="middle" rowspan="1" colspan="1">32.4 &#x000b1; 8.6 <sup>a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Max age, years</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="center" valign="middle" rowspan="1" colspan="1">45</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">50</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Min age, years</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender, N</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Clinical features (N of participants)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age of onset<break/>Teenagers (13&#x02013;17 years old)<break/>Young adults (18&#x02013;35 years old)</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>0<break/>15</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>3<break/>12</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Disease onset<break/>Recent onset psychosis (&#x02264;24 months)<break/>Established (&#x0003e;24 months)<break/>DIP</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>1<break/>14<break/>0</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>0<break/>13<break/>2</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No. of hospitalizations (severity)<break/>0&#x02013;6 times<break/>&#x02265;7 times</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>12<break/>3</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>12<break/>3</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Treatment-resistant schizophrenia<break/>Yes<break/>No</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>1<break/>14</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>3<break/>12</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Family history of psychiatric illness, N<break/>Yes<break/>No</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>8<break/>7</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>9<break/>6</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>0<break/>15</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>1<break/>14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of illness<break/>1&#x02013;8 years<break/>9&#x02013;16 years<break/>&#x02265;17 years</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>3<break/>6<break/>6</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>6<break/>4<break/>5</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">On medication for schizophrenia<break/>Yes<break/>No</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>15<break/>0</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>15<break/>0</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Drugs with anti-toxoplasmic activity<break/>Yes<break/>No</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>6<break/>9</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>13<break/>2</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Illicit drugs<break/>Yes<break/>No</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>2<break/>13</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>4<break/>11</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>0<break/>15</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>0<break/>15</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Lifestyle (N of participants)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Having cat(s) as pet<break/>Yes<break/>No</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>7<break/>8</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>8<break/>7</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>8<break/>7</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>10<break/>5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Smoking<break/>Yes<break/>No</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>5<break/>10</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>6<break/>9</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>1<break/>14</td><td align="center" valign="middle" rowspan="1" colspan="1"><break/>0<break/>15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alcohol intake<break/>Yes<break/>No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>4<break/>11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>2<break/>13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>0<break/>15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>1<break/>14</td></tr></tbody></table><table-wrap-foot><fn><p>NA: data not available; DIP: drug-induced psychosis; TP+NSz: non-schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+NSz: non-schizophrenia subjects without <italic toggle="yes">Toxoplasma</italic> infection; TP+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection. Data were analysed using ANOVA and Tukey post hoc test with <italic toggle="yes">p</italic> &#x0003c; 0.05 considered as statistically significant; <sup>a</sup> compared with TP+Sz.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="genes-13-01482-t002"><object-id pub-id-type="pii">genes-13-01482-t002_Table 2</object-id><label>Table 2</label><caption><p>Number of total, differentially expressed and identified MFs in different group comparisons.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Numbers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TP+NSz<break/>vs.<break/>TN+NSz</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TP+Sz<break/>vs.<break/>TN+Sz</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TN+Sz<break/>vs.<break/>TN+NSz</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TP+Sz<break/>vs.<break/>TP+NSz</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Total MFs</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive ion mode</td><td align="center" valign="middle" rowspan="1" colspan="1">1031</td><td align="center" valign="middle" rowspan="1" colspan="1">1031</td><td align="center" valign="middle" rowspan="1" colspan="1">1031</td><td align="center" valign="middle" rowspan="1" colspan="1">1031</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Negative ion mode</td><td align="center" valign="middle" rowspan="1" colspan="1">611</td><td align="center" valign="middle" rowspan="1" colspan="1">611</td><td align="center" valign="middle" rowspan="1" colspan="1">611</td><td align="center" valign="middle" rowspan="1" colspan="1">611</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>DeMFs</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Positive ion mode</td><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">46</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Negative ion mode</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Total identified DeMFs *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p>* only molecular features (MFs) identified at level 2 confidence annotation were reported; TP+NSz: non-schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+NSz: non-schizophrenia subjects without <italic toggle="yes">Toxoplasma</italic> infection; TP+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="genes-13-01482-t003"><object-id pub-id-type="pii">genes-13-01482-t003_Table 3</object-id><label>Table 3</label><caption><p>List of DeMFs in different group comparisons.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Metabolites</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Molecular Weight</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Retention Time (min)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Database ID</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Fold Change *<break/>(FDR)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP+NSz/<break/>TN+NSz</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP+Sz/<break/>TN+Sz</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TN+Sz/<break/>TN+NSz</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TP+Sz/<break/>TP+NSz</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">3,3&#x02032;-Thiopropionic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">178.02893</td><td align="center" valign="middle" rowspan="1" colspan="1">1.77</td><td align="center" valign="middle" rowspan="1" colspan="1">mzc3298</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;6.9<break/>(7.8 &#x000d7; 10<sup>&#x02212;5</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.2<break/>(2.1 &#x000d7; 10<sup>&#x02212;4</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x003b1;-Hydroxyglutaric acid</td><td align="center" valign="middle" rowspan="1" colspan="1">148.03596</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">mzc372</td><td align="center" valign="middle" rowspan="1" colspan="1">+2.1<break/>(0.016)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">+2.8<break/>(1.8 &#x000d7; 10<sup>&#x02212;7</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adenosine monophosphate</td><td align="center" valign="middle" rowspan="1" colspan="1">347.06249</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">mzc252</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.2<break/>(0.017)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.8<break/>(3.6 &#x000d7; 10<sup>&#x02212;4</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caprolactam</td><td align="center" valign="middle" rowspan="1" colspan="1">113.08415</td><td align="center" valign="middle" rowspan="1" colspan="1">2.86</td><td align="center" valign="middle" rowspan="1" colspan="1">mzc2867</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">+1.9<break/>(5.7 &#x000d7; 10<sup>&#x02212;8</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">+2.0<break/>(2.4 &#x000d7; 10<sup>&#x02212;8</sup>)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypoxanthine</td><td align="center" valign="middle" rowspan="1" colspan="1">136.03832</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" rowspan="1" colspan="1">mzc441</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;4.2<break/>(0.017)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;12.3<break/>(3.4 &#x000d7; 10<sup>&#x02212;8</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Inosine</td><td align="center" valign="middle" rowspan="1" colspan="1">268.08026</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">mzc1234</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;5.1<break/>(0.013)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;148.8<break/>(4.7 &#x000d7; 10<sup>&#x02212;10</sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Triisopropanolamine</td><td align="center" valign="middle" rowspan="1" colspan="1">191.15198</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95</td><td align="center" valign="middle" rowspan="1" colspan="1">mzc2688</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;2.6<break/>(0.002)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xanthine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">152.03229</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mzc781</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.7<break/>(0.049)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>*: relative change compared to the denominator; FDR: false discovery rate of <italic toggle="yes">t</italic>-test; +: up-regulated; &#x02212;: down-regulated; mzc: mzCloud database ID; TP+NSz: non-schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+NSz: non-schizophrenia subjects without <italic toggle="yes">Toxoplasma</italic> infection; TP+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection; TN+Sz: schizophrenia subjects with <italic toggle="yes">Toxoplasma</italic> infection.</p></fn></table-wrap-foot></table-wrap></floats-group></article>